ArticleAnnals of the rheumatic diseases2020
Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors.
Article in Annals of the rheumatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Rheumatoid arthritis and risk of site-specific cancers: Mendelian randomization study in European and East Asian populations.Arthritis research & therapy · 2022Pooled it
- Association Between Rheumatoid Arthritis and Survival After Cancer: A Systematic Literature Review and Meta-analysis.ACR open rheumatology · 2026Article
- Comparative disproportionality signals for methotrexate monotherapy versus methotrexate combined with hydroxychloroquine, leflunomide, or sulfasalazine in rheumatoid arthritis: newly highlighted signals evaluated using drug information safety profiles.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Nature's Pharmacy: Herbal Interventions in Rheumatoid Arthritis Treatment: A Comprehensive Review.Current rheumatology reviews · 2025Review
- Case report of concurrent ulcerative colitis and bilateral breast cancer: a literature review of the bidirectional association between autoimmune diseases and breast cancer.Frontiers in oncology · 2025Article
- Does autoimmune disease impair the survival of hepatocellular carcinoma patients undergoing liver resection? A multi-institutional observational study.Journal of cancer research and clinical oncology · 2024Observational
- Rheumatoid arthritis and cancer risk in the Million Women Study.International journal of epidemiology · 2024Article
- Identification and Verification of Novel Biomarkers Involving Rheumatoid Arthritis with Multimachine Learning Algorithms: An In Silicon and In Vivo Study.Mediators of inflammation · 2024Article
- Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study.The Lancet regional health. Europe · 2023Article
- Solid Cancers and Rheumatoid Arthritis.Cancers · 2023Article
- Tumor-Associated and Systemic Autoimmunity in Pre-Clinical Breast Cancer among Post-Menopausal Women.Biomolecules · 2023Article
- Large-scale real-world data analyses of cancer risks among patients with rheumatoid arthritis.International journal of cancer · 2023Article
- Musculoskeletal Pain and the Prevalence of Rheumatoid Arthritis in Breast Cancer Patients During Cancer Treatment: A Retrospective Study.Journal of breast cancer · 2022Article
- Cancer risks in rheumatoid arthritis patients who received immunosuppressive therapies: Will immunosuppressants work?Frontiers in immunology · 2022Article
- High Follicle-Stimulating Hormone Level Associated With Risk of Rheumatoid Arthritis and Disease Activity.Frontiers in endocrinology · 2022Article
- Analysis and Experimental Validation of Rheumatoid Arthritis Innate Immunity Gene CYFIP2 and Pan-Cancer.Frontiers in immunology · 2022Article
- What is the impact of sex hormones on the pathogenesis of rheumatoid arthritis?Frontiers in medicine · 2022Review
- Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer.Frontiers in oncology · 2022Review
- The association between plasma chemokines and breast cancer risk and prognosis: A mendelian randomization study.Frontiers in genetics · 2022Article
- Etiology and Risk Factors for Rheumatoid Arthritis: A State-of-the-Art Review.Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo examine the risk of incident breast cancer in women with rheumatoid arthritis (RA), and the risk of RA in women with a history of breast cancer, taking antihormonal treatment for breast cancer into account.
methodsUsing nationwide Swedish registers, women with new-onset RA diagnosed in 2006-2016 were identified and analysed using a cohort and a case-control design. Each patient with RA was matched on age, sex and place of residence to five randomly selected subjects from the general population. Through register linkages, we collected information on breast cancer, breast cancer risk factors (reproductive history and hormone replacement therapy) and socio-economy. The relative risk of breast cancer after RA was assessed using Cox regression, and the relative risk of RA in women with a history of breast cancer was assessed using conditional logistic regression.
resultsThe risk of incident breast cancer in women with RA was reduced and the association was not attenuated by adjustment for breast cancer risk factors (HR=0.80, 95% CI 0.68 to 0.93). The risk of RA in women with a history of breast cancer was similarly reduced (OR=0.87, 95% CI 0.79 to 0.95). Women with breast cancer treated with tamoxifen (OR=0.86, 95% CI 0.62 to 1.20) or aromatase inhibitors (OR=0.97, 95% CI 0.69 to 1.37) did not have an increased risk of RA compared with women with breast cancer treated differently.
conclusionsThe decreased occurrence of breast cancer in patients with RA is present already before RA diagnosis; these reduced risks are not readily explained by hormonal risk factors. Adjuvant antihormonal therapy for breast cancer does not seem to increase RA risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.